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Transglutaminase in Meat Products 
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In food processing, the enzyme transglutaminase (TG) is used as a “glue” to combine small 
pieces of meat into large chunks. Usually, transglutaminase of microbiological origin is used 
(mTG). In the general public, the enzyme has in the past been discussed in connection with 
so-called “glue ham”. During that discussion, the question came up whether mTG, when 
added to food, pose health risks for patients suffering from celiac disease. Research results 
on mTG in “enzyme glued ham” do not suggest that the enzyme itself (even in its active 
form) poses a relevant health risk in healthy persons without any impairment of their 
digestive function. What is known is that mTG can form various protein compounds 
(“enzymatic cross-linking”). Due to a lack of available data, it is currently not possible to 
assess these. The BfR has information from experimental studies indicating that mTG can, 
together with food proteins, form compounds that are structurally similar to gluten, gluten 
being responsible for the well-known immunological effects found in celiac patients. 
However, whether this results in health risks for these patients such as the typical effect of 
causing damage to the intestinal mucosa is not known for certain at present. To the extent 
that sufficient clinical studies on this are not available, a clinically relevant risk through 
microbial transglutaminase is possible for celiac disease sufferers. Suitable labelling of foods 
produced using mTG would enable these patients to avoid the uncertainties that the scientific 
community has yet to clarify. In addition, such labelling would ensure that all consumers are 
better informed on the use of “enzyme glue”. One way of inactivating mTG in the food 
product is thermal treatment. The existing data suggest that a risk for those affected by celiac 
disease, if it exists at all, could be virtually excluded thereby. The decisive issue continues to 
be that celiac disease can only be managed successfully, if patients avoid gluten altogether. 
 
The full version of the BfR Information in German is available on 
http://www.bfr.bund.de/cm/343/transglutaminase-in-fleischerzeugnissen.pdf 
Seite 1 von 1 
